Want to see AU:HXL full AI Analyst Report?
Top Page
Hexima Ltd
(Sydney:HXL)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.01
▲(20.00% Upside)
Action:Reiterated
Date:08/04/26
The score is primarily held down by weak financial performance, including persistent losses, near-zero recent revenue, and ongoing negative operating/free cash flow (cash burn). A low-debt balance sheet provides some risk mitigation, while technicals show only modest trend support with weak momentum confirmation. Valuation is also limited by negative earnings and no dividend yield.
Positive Factors
Low leverage
A near-zero debt position materially reduces refinancing and interest-rate risk, giving management runway to fund development or absorb setbacks. For a cash-burning biotech, low leverage preserves strategic optionality for partnerships or milestone-based financing over the next several months.
Negative Factors
Persistent operating losses
Chronic negative EBIT and net losses erode equity and limit internal capital generation. Over the medium term this constrains funding options, forces management to rely on external financing or dilution, and raises execution risk for advancing clinical programs to value-inflecting milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
A near-zero debt position materially reduces refinancing and interest-rate risk, giving management runway to fund development or absorb setbacks. For a cash-burning biotech, low leverage preserves strategic optionality for partnerships or milestone-based financing over the next several months.
Read all positive factors
Hexima Ltd (HXL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.17M
Dividend Yield0%
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)-0.07
Revenue GrowthN/A
EPS Growth50.00%
CountryAU
EmployeesN/A
SectorFinancial
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding41,759,846
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$45.80M
Hexima Ltd Business Overview & Revenue Model
Company Description
Hexima Limited is a biotechnology firm focused on the discovery and advancement of plant-derived proteins and peptides for medical applications in humans. Its primary drug candidate, pezadeftide, a plant defensin, is presently undergoing Phase IIb...
How the Company Makes Money
null...
Hexima Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 1.48M | 5.81M | 4.08M |
| Gross Profit | 0.00 | 0.00 | 1.47M | 5.67M | 3.93M |
| EBITDA | -503.83K | -995.54K | -3.08M | -15.21M | -10.34M |
| Net Income | -503.83K | -933.87K | -1.92M | -10.02M | -6.87M |
Balance Sheet | |||||
| Total Assets | 1.56M | 2.27M | 2.96M | 10.75M | 8.58M |
| Cash, Cash Equivalents and Short-Term Investments | 1.54M | 2.23M | 2.19M | 3.96M | 3.42M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 32.00K |
| Total Liabilities | 40.70K | 248.67K | 174.45K | 6.19M | 5.53M |
| Stockholders Equity | 1.52M | 2.02M | 2.78M | 4.57M | 3.05M |
Cash Flow | |||||
| Free Cash Flow | -637.19K | -161.90K | -1.76M | -9.76M | -5.79M |
| Operating Cash Flow | -637.19K | -161.90K | -1.76M | -9.76M | -5.79M |
| Investing Cash Flow | 46.79K | 98.00K | 38.97K | -1.80K | -903.00 |
| Financing Cash Flow | -100.00K | 100.00K | -3.66K | 10.34M | 7.90M |
Hexima Ltd Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HXL, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of 0.00 is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HXL.
Hexima Ltd Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
44 Neutral | AU$6.10M | -7.14 | -45.29% | 9.09% | 290.25% | 92.05% | |
44 Neutral | AU$49.26M | -0.62 | -118.74% | ― | 499.47% | 31.20% | |
43 Neutral | AU$367.33M | -46.78 | -42.35% | ― | 145.32% | 25.75% | |
42 Neutral | AU$2.17M | -5.42 | -14.90% | 0.00% | ― | 50.00% | |
42 Neutral | AU$102.43M | -6.66 | 84.67% | ― | ― | 42.51% | |
32 Underperform | AU$4.96M | -0.93 | -52.04% | ― | 32.22% | -26.53% |
* Financial Sector Average
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
AU:ACR
Acrux
0.01
>-0.01
-33.33%
AU:SPL
Starpharma Holdings Limited
0.80
0.67
534.92%
AU:TRP
Tissue Repair Ltd
0.08
-0.20
-70.71%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.11
-84.62%
AU:RCE
Recce Pharmaceuticals Ltd.
0.35
-0.06
-13.75%
Hexima Ltd Corporate Events
Hexima Shrinks Cash Base After Capital Return to Shareholders
Jul 31, 2026
Hexima Limited has provided its quarterly activities report for the three months to 30 June 2026, highlighting a continued emphasis on capital management and minimal operating activity. The company has effectively become a cash shell, with expendi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.